Product
RBX2660
Aliases
microbiota suspension, Microbiota suspension, REBYOTA®
3 clinical trials
4 indications
Indication
Clostridium difficile infectionIndication
InfectionIndication
Infectious DiseasesClinical trial
A Phase 3 Open-Label Clinical Study to Evaluate the Safety and Tolerability of Rebiotix RBX2660 (Microbiota Suspension) in Subjects With Recurrent Clostridium Difficile InfectionStatus: Completed, Estimated PCD: 2023-07-21
Clinical trial
A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile InfectionStatus: Recruiting, Estimated PCD: 2025-01-16
Clinical trial
A Phase 3 Prospective, Randomized, Double-blinded, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of RBX2660 (Microbiota Suspension) for the Prevention of Clostridium Difficile InfectionStatus: Completed, Estimated PCD: 2020-04-02